Compare SMJF & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMJF | CYPH |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | 6 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 73.4M |
| IPO Year | N/A | N/A |
| Metric | SMJF | CYPH |
|---|---|---|
| Price | $5.19 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 692.9K | ★ 6.4M |
| Earning Date | 09-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $68.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.49 |
| 52 Week High | $5.70 | $3.70 |
| Indicator | SMJF | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.04 | 38.20 |
| Support Level | $4.86 | $0.54 |
| Resistance Level | $5.61 | $0.81 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 53.85 | 19.41 |
SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, broadloom carpets and vinyl tiles. The company operates under the proprietary brand 'SMJ'.The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. It has presence in several countries including Malaysia, Indonesia, Philippines, Hong Kong, PRC, Taiwan, Korea, Thailand, Vietnam, Brunei, and India. It generates revenue mainly through the sale and distribution of its flooring products prominently in Singapore.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.